Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
NEW YORK (Reuters Health) – While angiotensin receptor blockers (ARBs) as a class do not appear to be associated with an increased malignancy risk in patients with diabetes,…
NEW YORK (Reuters Health) – Some patients with metastatic clear-cell renal cancer appear to fare relatively well when treated with sunitinib before undergoing planned nephrectomy — even though…
NEW YORK (Reuters Health) – Using intra-arterial chemotherapy to treat retinoblastoma can produce a “dramatic response,” but also comes with the risk of both mild and severe side…
NEW YORK (Reuters Health) – Women who are positive for human papilloma virus (HPV) and have low-grade cervical cytological abnormalities but normal colposcopic findings are at low risk…
NEW YORK (Reuters Health) – While partial nephrectomy remains the gold standard for treatment of small renal masses, laparoscopic cryoablation is a good option for selected patients, an…
NEW YORK (Reuters Health) – Hysteroscopy using narrow-band imaging (NBI) technology may be more sensitive than white-light imaging (WLI) for diagnosing endometrial cancer and hyperplasia, hint results of…
NEW YORK (Reuters Health) – After chemotherapy-induced remission of follicular lymphoma, vaccination with a patient-specific tumor-derived antigen improves disease-free survival, a multicenter team has shown. Furthermore, the vaccine…
NEW YORK (Reuters Health) – The longitudinal decline in lung function seen in patients with common variable immunodeficiency and X-linked agammaglobulinemia is related to immunoglobulin replacement level and…
NEW YORK (Reuters Health) – Very small breast tumors that generate extensive lymph node involvement may be more biologically aggressive than larger tumors with the same degree of…
NEW YORK (Reuters Health) – Results of a meta-analysis confirm that the oral tyrosine kinase inhibitor gefitinib is effective as first-line therapy in patients with advanced non-small-cell lung…
